Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease.
about
Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detectionA glance at subgenomic flavivirus RNAs and microRNAs in flavivirus infectionsGenome-wide analysis of microRNA and mRNA expression signatures in cancerExploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer PatientsMicro-RNAs as diagnostic or prognostic markers in human epithelial malignanciesThe circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluidsSignificance and therapeutic value of miRNAs in embryonal neural tumorsSystemic mirnas as potential biomarkers for malignancyMicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancerCirculating microRNAs: potential biomarkers for common malignanciesIdentification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast CancerMicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine.Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy.Computational prediction of disease microRNAs in domestic animalsFar beyond the usual biomarkers in breast cancer: a review.MicroRNA-21 identified as predictor of cancer outcome: a meta-analysisThe clinicopathological significance of microRNA-155 in breast cancer: a meta-analysisNoncoding RNAs as novel biomarkers in prostate cancer.microRNA alterations in ALDH positive mammary epithelial cells: a crucial contributing factor towards breast cancer risk reduction in case of early pregnancy.Circulating miR-148b and miR-133a as biomarkers for breast cancer detection.Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy.MicroRNA profile in very young women with breast cancerEffects of age on the detection and management of breast cancer.Relationship between circulating and tissue microRNAs in a murine model of breast cancerCirculating microRNAs as a novel class of diagnostic biomarkers in gastrointestinal tumors detection: a meta-analysis based on 42 articles.Clinical implications of microRNAs in cancer.Role of deregulated microRNAs in breast cancer progression using FFPE tissue.Dampening enthusiasm for circulating microRNA in breast cancer.MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons.The association between abnormal microRNA-10b expression and cancer risk: a meta-analysis.miR-379 regulates cyclin B1 expression and is decreased in breast cancer.microRNA-339-5p modulates Na+/I- symporter-mediated radioiodide uptake.In-depth characterization of microRNA transcriptome in melanoma.Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies.miRNA - Therapeutic tool in breast cancer? Where are we now?Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarkerMicroRNA-155 hallmarks promising accuracy for the diagnosis of various carcinomas: results from a meta-analysis.MiR-16 family as potential diagnostic biomarkers for cancer: a systematic review and meta-analysisMicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid.Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients.
P2860
Q21134914-B27A596E-89CB-4BDA-9C2A-CE1D239D5AC9Q26745536-27DBFD41-381E-485D-A4BD-3DBC20557766Q26795603-C5EBA7E9-890C-4390-B861-9BF3ABE6A0C0Q26796590-53F17A81-C8CB-49E4-A584-32775C23D9F2Q26823077-A45D779A-C420-4458-BA28-B237B0A9EE33Q26825022-00071992-79C0-4047-8667-4BDF18B0C3D3Q26827171-43D1274B-6D74-45AB-B544-2CE3322F78CEQ27004655-65F1CAF0-2D8A-4540-B93C-660697CBAACCQ27022048-53C8F451-9715-4435-84C4-1507B2B87955Q28081347-0AC5377E-FDF7-4D7A-A67F-D159F003BADDQ28552581-2589F07D-98E9-4917-81F2-2117125C7A5BQ33733403-6D214D40-A319-437E-B920-51277F607865Q33844289-923FBE91-DAD1-48A3-9F03-4469D8317FC0Q33881021-FDC3FD1D-29C1-483E-BDC6-79B3C3B30107Q33935217-F6844E5C-02C1-4CD5-86F2-C5F58EE755B9Q34010854-D33ACEBA-1CF6-466E-8F23-5FE21A49FD07Q34064171-468CAFC6-A9A5-492E-8FD8-616CEFD77062Q34176890-8776F040-FE92-46B0-830F-55E729BFCB81Q34204974-EE4F64EC-4A63-4896-9016-773AFC460C8FQ34221705-2FB76471-A47A-4890-9F2E-76779F9811D4Q34426839-6AA88A0D-EB62-4A3C-9EFC-581FC2F91B42Q34468715-6CE07495-AFF3-4E85-B259-6385308F2E49Q34477879-568519D0-746E-40D6-9D1A-1ADAC17CA03EQ34505424-CD64FAC2-BB1E-408D-A3B1-974DA5C78325Q34535929-6CB523F6-08EA-4125-BE28-34CB63672AC1Q34570698-1CC3DABA-C22E-4B85-A78B-DEC2366BA260Q34571026-4B268C44-CAA2-48A6-B187-499F0F022534Q34614489-604A8350-9436-46C8-A298-8447632D52AAQ34685896-74A8DD83-6092-4444-A2D4-DD3F927DC2CEQ34708173-037E7D85-D689-4CA5-B167-191477838A05Q34850908-4303F6FE-5BEF-46A5-BDF6-3D9F2124AC60Q34982847-6EA98E60-21BC-4703-A972-8DC57B76D3A7Q34984013-9D82060E-241E-4573-8022-5F8A2EF58DD4Q35082591-1DF71074-7A5A-438D-839A-F6660A04ADF9Q35113386-670F93DF-6086-4074-9F22-C3F55C1AD172Q35247522-42A6ACCC-DFE7-4963-9D40-E30F0F6D3E99Q35415884-8C0D9B20-52D0-4D7E-AD9F-1F8D6D80541BQ35479266-93066480-7DE6-49CF-A34C-B465EE04E6C5Q35588426-060C2D1C-A8F0-4006-ACA8-66F7EE995476Q35683533-E6E35150-7A79-4E71-9D15-76C55B44D264
P2860
Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Systemic miRNA-195 differentia ...... asive and early stage disease.
@ast
Systemic miRNA-195 differentia ...... asive and early stage disease.
@en
type
label
Systemic miRNA-195 differentia ...... asive and early stage disease.
@ast
Systemic miRNA-195 differentia ...... asive and early stage disease.
@en
prefLabel
Systemic miRNA-195 differentia ...... asive and early stage disease.
@ast
Systemic miRNA-195 differentia ...... asive and early stage disease.
@en
P2093
P2860
P1433
P1476
Systemic miRNA-195 differentia ...... asive and early stage disease.
@en
P2093
Michael J Kerin
Nicola Miller
Ronan Kelly
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0103
P577
2010-06-24T00:00:00Z